Jama Oncology最新文献

筛选
英文 中文
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. MGMT甲基化胶质母细胞瘤患者在替莫唑胺基础上加用Veliparib的疗效:随机临床试验
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4361
Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini, Bret B Friday, Nicholas A Butowski, Nimish A Mohile, David E Piccioni, James D Battiste, Jan Drappatz, Jian L Campian, Sandeep Mashru, Kurt A Jaeckle, Barbara J O'Brien, Jesse G Dixon, Brian F Kabat, Nadia L Laack, Leland S Hu, Timothy Kaufmann, Priya Kumthekar, Benjamin M Ellingson, S Keith Anderson, Evanthia Galanis
{"title":"Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.","authors":"Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini, Bret B Friday, Nicholas A Butowski, Nimish A Mohile, David E Piccioni, James D Battiste, Jan Drappatz, Jian L Campian, Sandeep Mashru, Kurt A Jaeckle, Barbara J O'Brien, Jesse G Dixon, Brian F Kabat, Nadia L Laack, Leland S Hu, Timothy Kaufmann, Priya Kumthekar, Benjamin M Ellingson, S Keith Anderson, Evanthia Galanis","doi":"10.1001/jamaoncol.2024.4361","DOIUrl":"10.1001/jamaoncol.2024.4361","url":null,"abstract":"<p><strong>Importance: </strong>The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields.</p><p><strong>Objectives: </strong>To evaluate the combination of veliparib and temozolomide in glioblastoma based on preclinical data demonstrating significant chemosensitizing effects of the polyadenosine diphosphate-ribose polymerase 1/2 inhibitor veliparib when combined with temozolomide.</p><p><strong>Design, setting, and participants: </strong>Patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation who had completed concomitant radiation and temozolomide were enrolled between December 15, 2014, and December 15, 2018, in this Alliance for Clinical Trials in Oncology trial. The data for this analysis were locked on April 21, 2023.</p><p><strong>Interventions: </strong>Patients were randomized and treated with standard adjuvant temozolomide (150-200 mg/m2 orally, days 1-5) combined with either placebo or veliparib (40 mg orally, twice daily, days 1-7) for 6 cycles.</p><p><strong>Main outcomes and measures: </strong>The primary end point for the phase 3 portion of the trial was overall survival (OS).</p><p><strong>Results: </strong>There were 322 patients randomized during the phase 2 accrual period and an additional 125 patients randomized to complete the phase 3 accrual, for a total of 447 patients in the final phase 3 analysis. The median (range) age for patients was 60 (20-85) years and 190 patients (42.5%) were female. The median OS was 24.8 months (90% CI, 22.6-27.7) for the placebo arm and 28.1 months (90% CI, 24.3-33.3) for the veliparib arm (P = .17). The difference in survival did not meet the prespecified efficacy end point. However, there was a separation of the survival curves that favored the veliparib arm over 24 to 48 months of follow-up. The experimental combination was well tolerated with an acceptable elevation in grade 3 or 4 hematologic toxic effects.</p><p><strong>Conclusions and relevance: </strong>This trial found that adding veliparib to adjuvant temozolomide did not significantly extend OS in patients with newly diagnosed, MGMT-hypermethylated glioblastoma.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02152982.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Figure 3. 图 3 中的错误。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.5240
{"title":"Errors in Figure 3.","authors":"","doi":"10.1001/jamaoncol.2024.5240","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.5240","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
metastatic. 转移。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4899
Tega Ebeye
{"title":"metastatic.","authors":"Tega Ebeye","doi":"10.1001/jamaoncol.2024.4899","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4899","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of the Oncology Industrial Complex on Academic Cancer Centers. 肿瘤学工业综合体对癌症学术中心的影响。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4876
S Gail Eckhardt, Leonidas C Platanias
{"title":"Effects of the Oncology Industrial Complex on Academic Cancer Centers.","authors":"S Gail Eckhardt, Leonidas C Platanias","doi":"10.1001/jamaoncol.2024.4876","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4876","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis. 癌症诊断后早期干预戒烟治疗的生存效果。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4890
Paul M Cinciripini, George Kypriotakis, Janice A Blalock, Maher Karam-Hage, Diane M Beneventi, Jason D Robinson, Jennifer A Minnix, Graham W Warren
{"title":"Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis.","authors":"Paul M Cinciripini, George Kypriotakis, Janice A Blalock, Maher Karam-Hage, Diane M Beneventi, Jason D Robinson, Jennifer A Minnix, Graham W Warren","doi":"10.1001/jamaoncol.2024.4890","DOIUrl":"10.1001/jamaoncol.2024.4890","url":null,"abstract":"<p><strong>Importance: </strong>Smoking after a cancer diagnosis increases mortality and risk for a second cancer.</p><p><strong>Objective: </strong>To determine the association between time of entry into a smoking cessation intervention following a cancer diagnosis and survival outcomes.</p><p><strong>Design, setting, and participants: </strong>Using a prospective cohort study design, patients with cancer who smoked and received cessation treatment were assessed at 3 months, 6 months, and 9 months following tobacco treatment onset. Survival outcomes of tobacco treatment were measured and compared among patients at the MD Anderson Cancer Center Tobacco Research and Treatment Program. Treatment occurred between January 1, 2006, and March 3, 2022. Patients were excluded if they died before the tobacco treatment ended, received their diagnosis more than 6 months after beginning cessation treatment, or lacked staging information. The data analysis took place from September 2023 to May 2024.</p><p><strong>Interventions: </strong>Cessation treatment consisted of 6 to 8 personalized counseling visits and 10 to 12 weeks of pharmacotherapy. More than 95% of visits were provided via telemedicine.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were survival as recorded in the MD Anderson Cancer Center tumor registry and 7-day point prevalence abstinence at each follow-up.</p><p><strong>Results: </strong>The main analytical sample consisted of 4526 currently smoking patients diagnosed with cancer and receiving cessation treatment (2254 [49.8%] female; median [IQR] age, 55 [47-62] years). Survival over 15 years increased for those quitting smoking at 3 months (adjusted hazard ratio [aHR], 0.75 [95% CI, 0.67-0.83]), 6 months (aHR, 0.79 [95% CI, 0.71-0.88]), and 9 months (aHR, 0.85 [95% CI, 0.76-0.95]) of follow-up. The optimal survival outcomes were observed for patients who received tobacco treatment within 6 months of a cancer diagnosis. At the 75th percentile, their survival increased from 2.1 years (95% CI, 1.8-2.4 years) among continuing smokers (nonabstainers) vs 3.9 years (95% CI, 3.2-4.6 years) for patients who quit (abstainers). Similar but less pronounced outcomes were noted when tobacco treatment began within 6 months to 5 years following diagnosis, with survival at the 75th percentile of 4.8 years (95% CI, 4.3-5.3 years) for nonabstainers vs 6.0 years (95% CI, 5.1-7.2 years) for abstainers.</p><p><strong>Conclusions and relevance: </strong>The results of this prospective cohort study suggest that evidence-based smoking cessation treatment within 6 months following a cancer diagnosis maximizes survival benefit. This study supports smoking cessation as an important early clinical intervention for patients after being diagnosed with cancer.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine. 通过远程医疗扩大数字时代临床试验的可及性。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4908
Jiatong Ding, Shuhang Wang, Ning Li
{"title":"Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine.","authors":"Jiatong Ding, Shuhang Wang, Ning Li","doi":"10.1001/jamaoncol.2024.4908","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4908","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine-Reply. 通过远程医疗扩大数字时代临床试验的可及性--回复。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-31 DOI: 10.1001/jamaoncol.2024.4911
Wade T Swenson
{"title":"Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine-Reply.","authors":"Wade T Swenson","doi":"10.1001/jamaoncol.2024.4911","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4911","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer. 就《晚期前列腺癌中的心血管事件和雄激素受体信号抑制剂》发表评论。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-17 DOI: 10.1001/jamaoncol.2024.4581
Yubo Tang, Qingde Wa, Shuai Huang
{"title":"Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer.","authors":"Yubo Tang, Qingde Wa, Shuai Huang","doi":"10.1001/jamaoncol.2024.4581","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.4581","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Error in Byline. 标题有误。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-17 DOI: 10.1001/jamaoncol.2024.5097
{"title":"Error in Byline.","authors":"","doi":"10.1001/jamaoncol.2024.5097","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.5097","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer. 大肠癌患者的错配修复和微卫星检测
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-03 DOI: 10.1001/jamaoncol.2024.4342
Totadri Dhimal, Fernando Colugnati, Bailey K Hilty Chu, Anthony Loria, Paula Cupertino, Daniel Mulkerin, Fergal J Fleming
{"title":"Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer.","authors":"Totadri Dhimal, Fernando Colugnati, Bailey K Hilty Chu, Anthony Loria, Paula Cupertino, Daniel Mulkerin, Fergal J Fleming","doi":"10.1001/jamaoncol.2024.4342","DOIUrl":"10.1001/jamaoncol.2024.4342","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":null,"pages":null},"PeriodicalIF":28.4,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信